VYGR

Voyager Therapeutics Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↓ 0/10
  • Momentum↓ 3/10
Voyager Therapeutics sales and earnings growth
VYGR Growth
Low
  • Revenue Y/Y↓ -80.88%
  • EPS Y/Y↓ -414.49%
  • FCF Y/Y↓ -314.69%
Voyager Therapeutics gross and profit margin trends
VYGR Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -404.80%
  • ROIC↓ -45.70%
Voyager Therapeutics net debt vs free cash flow
VYGR Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Voyager Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗